Oppenheimer Reiterates Outperform Rating on Capricor Therapeutics (CAPR) Ahead of Presentaion

September 17, 2026 10:28 AM

Oppenheimer analyst Leland Gershall reiterated an Outperform rating and $54.00 price target on Capricor Therapeutics (NASDAQ: CAPR) after the company ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found